News

15th June 2017 – The Pulse recently interviewed Dr Scott Pollack, Associate Director, Biophysics and Enzymology, and Dr Paul Clewlow, Senior VP, Business Development, about how Sygnature Discovery is accelerating their ambitious clients’ drug discovery programs and helping them to increase their productivity through the application of cutting-edge technology, such as the Biacore 8K surface […]

14th June 2017 – What a difference a year makes! Chemistry World caught up with Dr Simon Hirst, Sygnature Discovery’s Founder and CEO, one year after he was named as the Royal Society of Chemistry’s ‘Chemistry World Entrepreneur of the Year’ 2016. Since then the company has risen to even great heights and now […]

1st June 2017 – SelectScience recently interviewed Denise Swift, a Senior Bioscientist, Project and Team Leader at Sygnature Discovery. Denise is responsible for evaluating new technologies to enhance Sygnature’s Bioscience capabilities – in particular, screening technologies, instrumentation and automation. The interview highlighted Sygnature Discovery’s novel approach to custom assay development and revealed some of the […]

10th May 2017 – London, UK – The report is a celebration of the UK’s fastest-growing and most dynamic small and medium sized businesses across the UK. To be included in the list, companies needed to show consistent revenue growth over a minimum of three years, significantly outperforming their industry peers. More detail on the […]

2nd May 2017 – Nottingham, UK – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has enhanced its Biophysics capability with the addition of GE Healthcare’s Biacore 8K SPR system to the Biacore T200 SPR system that the company already has in-house. As the newest member of GE Healthcare’s […]